Sugemalimab
drugOn this page
Also known as CejemlyCS-1001Cs1001WBP-315WBP315
Summary
Sugemalimab (CHEMBL4594535) is an approved antibody (ATC L01FF11); indicated across 11 conditions including neoplasm and non-small cell lung carcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L01FF11
- Indications: 11 conditions
- Clinical trials: 18
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594535 |
| Name | Sugemalimab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L01FF11 |
Also known as: Cejemly, CS-1001, Cs1001, CS1001, Sugemalimab, WBP-315, WBP315, SUGEMALIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| non-small cell lung carcinoma | 4 | MONDO:0005233 | EFO:0003060 |
| gastric adenocarcinoma | 3 | MONDO:0005036 | EFO:0000503 |
| nasal cavity and paranasal sinus lethal midline granuloma | 3 | MONDO:0006828 | MONDO:0019472 |
| esophageal squamous cell carcinoma | 3 | MONDO:0005580 | EFO:0005922 |
| adenocarcinoma | 3 | MONDO:0004970 | MONDO:0003219 |
| Hodgkins lymphoma | 2 | MONDO:0004952 | EFO:0000183 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| small cell lung carcinoma | 2 | MONDO:0008433 | EFO:0000702 |
| hepatocellular carcinoma | 1 | MONDO:0007256 | EFO:0000182 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 18.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 6 |
| PHASE1 | 4 |
| PHASE2 | 3 |
| PHASE1/PHASE2 | 2 |
| Not specified | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03789604 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer |
| NCT05623267 | PHASE2/PHASE3 | RECRUITING | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT |
| NCT05700448 | PHASE3 | NOT_YET_RECRUITING | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma |
| NCT06617416 | PHASE3 | RECRUITING | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC |
| NCT03728556 | PHASE3 | COMPLETED | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer |
| NCT03802591 | PHASE3 | COMPLETED | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma |
| NCT04187352 | PHASE3 | COMPLETED | A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma |
| NCT05940532 | PHASE2 | RECRUITING | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC |
| NCT06217757 | PHASE1/PHASE2 | RECRUITING | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC |
| NCT03505996 | PHASE2 | COMPLETED | A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma |
| NCT03595657 | PHASE2 | COMPLETED | A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) |
| NCT04200404 | PHASE1/PHASE2 | COMPLETED | A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors |
| NCT03312842 | PHASE1 | COMPLETED | A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors |
| NCT03744403 | PHASE1 | COMPLETED | A Study of CS1001 in Subjects with Advanced Solid Tumors |
| NCT04421352 | PHASE1 | COMPLETED | Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients |
| NCT04472858 | PHASE1 | UNKNOWN | A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors |
| NCT07247227 | Not specified | RECRUITING | Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC |
| NCT05131438 | Not specified | NO_LONGER_AVAILABLE | An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).